EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

How Patients with Atopic Dermatitis Experience Topical Therapy: A Real-World Analysis of Impact, Treatment Satisfaction, and HCP Communication

Peter Lio, Autumn Burnette, Alexa Hetzel, Evangeline J Pierce, Zach Dawson, Rosie Fielding, James Haughton, Sarah Weatherby, Linda Stein Gold

Dermatology and Therapy · 30.10.2026

DOI: 10.1007/s13555-026-01967-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology and Therapy, online erschienen am 30.10.2026. Verfasst von Peter Lio und 8 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atopic dermatitis (AD) is a chronic, burdensome skin condition with significant impact on quality of life. Topical therapies are recommended as first-line treatment; however, patients with moderate-to-severe disease or inadequate disease control may require escalation to systemic therapy. Despite the central role of topical therapies in AD management, real-world data on treatment satisfaction and healthcare provider (HCP)–patient concordance remain limited.

Methods

This analysis draws on data from the Adelphi Real World Atopic Dermatitis Topical Plus Wave I Disease Specific Programme (DSP)™, a cross-sectional, real-world survey conducted in 2025 among 267 US adolescents and adults with current moderate-to-severe AD. Using linked surveys, we evaluated treatment satisfaction and communication dynamics between HCPs and patients/caregivers using topical therapies, both with and without advanced systemic therapy. Kappa analysis assessed HCP–patient/caregiver agreement.

Results

At time of survey completion, 233 participants had moderate AD (87%), as assessed by a HCP, with 34 participants (13%) having severe AD. Participants in both the topical medication only (TM) ( n = 193; 72%) and topical plus advanced systemic therapy (TAS) ( n = 74; 28%) groups reported day-to-day impacts on clothing choices, daily activities, and sleep. Notably, 68% of patients using topical therapies reported disliking how their topical therapy made their skin feel, underscoring a persistent daily treatment burden. Regarding satisfaction, moderate concordance between patient/caregiver and HCP ratings was observed among individuals receiving TM ( κ = 0.57; p < 0.001) and those with moderate AD ( κ = 0.46; p < 0.001), with fair concordance among patients/caregivers receiving TAS ( κ = 0.27; p = 0.001) and those with severe AD ( κ = 0.25; p = 0.031). Communication analysis revealed moderate concordance between HCPs and patients/caregivers with respect to instructions for application amount (TM: κ = 0.54, p < 0.001; TAS κ = 0.42, p < 0.001).

Conclusions

These findings highlight persistent gaps in satisfaction and communication for patients with moderate-to-severe AD prescribed topical medications, underscoring the need for individualized treatment approaches. Addressing these gaps may help address unmet needs and inform more individualized care.

Schlagwörter

Stichwörter der Autor:innen

Atopic dermatitisPatient-reported outcomesTopical therapies

Autor:innen und Institutionen

  • Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Howard University Hospital, Washington, DC, USA.
  • Schweiger Dermatology Group, East Windsor, NJ, USA.
  • Eli Lilly and Company, 893 S. Delaware Street, Indianapolis, IN, 46285, USA. evangeline.pierce@lilly.com.
  • Eli Lilly and Company, 893 S. Delaware Street, Indianapolis, IN, 46285, USA.
  • Adelphi Real World, Bollington, UK.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Lio, P., Burnette, A., Hetzel, A., Pierce, E. J., Dawson, Z., Fielding, R., Haughton, J., Weatherby, S., & Stein Gold, L. (2026). How Patients with Atopic Dermatitis Experience Topical Therapy: A Real-World Analysis of Impact, Treatment Satisfaction, and HCP Communication. Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01967-9

Vancouver

Lio P, Burnette A, Hetzel A, Pierce EJ, Dawson Z, Fielding R, et al. How Patients with Atopic Dermatitis Experience Topical Therapy: A Real-World Analysis of Impact, Treatment Satisfaction, and HCP Communication. Dermatology and Therapy. 2026. doi:10.1007/s13555-026-01967-9

BibTeX
@article{Lio2026,
  author = {Lio, Peter and Burnette, Autumn and Hetzel, Alexa and Pierce, Evangeline J and Dawson, Zach and Fielding, Rosie and Haughton, James and Weatherby, Sarah and Stein Gold, Linda},
  title = {How Patients with Atopic Dermatitis Experience Topical Therapy: A Real-World Analysis of Impact, Treatment Satisfaction, and HCP Communication},
  journal = {Dermatology and Therapy},
  year = {2026},
  doi = {10.1007/s13555-026-01967-9}
}
Kostenlos starten →